Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Invest Ophthalmol Vis Sci ; 56(8): 4560-9, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26200496

RESUMEN

PURPOSE: To determine if sarpogrelate, a selective 5-HT2A receptor antagonist, is protective against light-induced retinopathy in BALB/c mice. METHODS: BALB/c mice were dosed intraperitoneally with 5, 15, 30, 40, or 50 mg/kg sarpogrelate 48, 24, and 0 hours prior to bright light exposure (10,000 lux) as well as 24 and 48 hours after exposure. Additionally, a single injection regimen was evaluated by injecting mice with 50 mg/kg sarpogrelate once immediately prior to light exposure. To investigate the potential for additive effects of serotonin receptor agents, a combination therapy consisting of sarpogrelate (15 mg/kg) and 8-OH-DPAT (1 mg/kg) was evaluated with the 5-day treatment regimen. Neuroprotection was characterized by the preservation of retinal thickness and function, measured by spectral-domain optical coherence tomography (SD-OCT) and electroretinography (ERG), respectively. RESULTS: Mice that were light damaged and injected with saline had significantly reduced outer retinal thickness, total retinal thickness, and ERG amplitudes compared with naïve mice. A 5-day administration of 15, 30, or 40 mg/kg of sarpogrelate was able to partially protect retinal morphology and full protection of retinal morphology was achieved with a 50 mg/kg dose. Both 15 and 30 mg/kg doses of sarpogrelate partially preserved retinal function measured by ERG, whereas 40 and 50 mg/kg doses fully preserved retinal function. Additionally, a single administration of 50 mg/kg sarpogrelate was able to fully preserve both retinal morphology and function. Administration of 15 mg/kg of sarpogrelate and 1 mg/kg of 8-OH-DPAT together demonstrated an additive effect and fully preserved retinal morphology. CONCLUSIONS: A 5- or 1-day treatment with 50 mg/kg sarpogrelate can completely protect the retina of BALB/c mice from light-induced retinopathy. Partial protection can be achieved with lower doses starting at 15 mg/kg and protection increases in a dose-dependent manner. Treatment with low doses of sarpogrelate and 8-OH-DPAT elicits an additive effect that results in full protection of retinal morphology.


Asunto(s)
Luz/efectos adversos , Traumatismos Experimentales por Radiación/prevención & control , Protectores contra Radiación/uso terapéutico , Retina/efectos de la radiación , Degeneración Retiniana/prevención & control , Antagonistas del Receptor de Serotonina 5-HT2/uso terapéutico , Succinatos/uso terapéutico , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacología , Animales , Modelos Animales de Enfermedad , Electrorretinografía , Inyecciones Intraperitoneales , Ratones , Ratones Endogámicos BALB C , Traumatismos Experimentales por Radiación/etiología , Traumatismos Experimentales por Radiación/patología , Protectores contra Radiación/administración & dosificación , Retina/patología , Degeneración Retiniana/etiología , Degeneración Retiniana/patología , Antagonistas del Receptor de Serotonina 5-HT2/administración & dosificación , Agonistas de Receptores de Serotonina/farmacología , Succinatos/administración & dosificación , Tomografía de Coherencia Óptica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA